Prostate Cancer Patients Top All Other Conditions Treated with Protons . . .
New Hopkins Study Says PSA Velocity Predicts Prostate Cancer Risk

The phenomenon continues among men diagnosed with prostate cancer that began with the opening in 1990 of Loma Linda University Medical Center’s proton facility. Prostate patients top all other cancerous conditions treated with proton therapy between the five U.S. operating protons centers. About 8,000 men have been treated with outstanding outcomes reported in the last 17 years –including two studies by researchers at Loma Linda. A vast majority of men self-referred themselves to proton treatment centers around the country after learning about the advantages of the proton beam that minimizes serious side effects and helps to maintain a patient’s quality-of-life.

Meantime, researchers at Johns Hopkins have found that PSA velocity can predict prostate cancer many years in advance when it is more curable. A new study by Hopkins and the National Institute on Aging found that an increase in PSA level of more than 0.75 ng/mL per year was an early predictor of prostate cancer in men with PSA levels between 4 and 10. PSA velocity is especially helpful in detecting early cancer in men with mildly elevated PSA levels and a normal digital rectal exam, according to the Hopkins study. It is most useful in predicting the presence of cancer when changes in PSA are elevated over at least one to two years.


> Send mail to with questions or comments about this web site.